Stocks › Biotechnology › TBPH

Theravance Biopharma(Delisted) TBPH

US equityMarket cap rank #3323Biotechnology

$17.03 +$0.00 (0.00%)

Market closed · Oct 8, 12:00 am ET

Open$0.00

Prev close$17.03

Day range$0.00 – $0.00

Volume0.00

Market cap$884.18M

P/E (TTM)16.4

Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership93.3%-0.20 pts vs. prior quarter

Institutions holding218+0 vs. prior quarter

Insider trades (recent)17 buys / 33 sellsNet selling

Short interest3.25% of floatDays to cover 4.5 · as of 15 Sep 2026

Short-sale volume share19.8%5-day average of daily volume

Short-sale volume as % of daily volume

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$3.16M (4 inflow days, 16 outflow days).

Net flow by order size, last 20 sessions

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 52.7% of shares outstanding.

Largest holders

Madison Avenue Partners, LP17.66%
Weiss Asset Management, LLC14.36%
BlackRock8.79%
Newtyn Management, LLC6.61%
Irenic Capital Management LP5.32%
Vanguard Capital Management, LLC3.94%
Rick Winningham3.33%
State Street Global Advisors2.56%

By investor type

Hedge Fund53.44%
Mutual Fund35.72%
Individual/Insider6.22%
Public Company2.25%
Private Company1.09%
Government Pension Fund0.59%
Family Office/Trust0.12%
Insurance Company0.07%

Reported short interest has fallen from 8.73% to 3.25% of float over the last 6 biweekly reports (30 Jun 2026 to 15 Sep 2026).

Recent institutional activity

Holder	Type	Period	Share change	New stake
Putnam Fiduciary Trust Company	Private Company	2026/Q3	+39,288	0.1%
Mackenzie Financial Corporation	Mutual Fund	2026/Q3	+737,166	1.9%
Citadel Advisors LLC	Hedge Fund	2026/Q3	+420,577	1.0%
Glazer Capital, LLC	Hedge Fund	2026/Q3	+301,834	0.6%
BlackRock	Mutual Fund	2026/Q3	+266,197	8.8%
D. E. Shaw & Co., L.P.	Hedge Fund	2026/Q3	+231,348	2.3%
Morgan Stanley	Public Company	2026/Q3	+158,333	1.1%
Qube Research & Technologies Ltd	Mutual Fund	2026/Q3	+140,340	0.8%
WEDGE Capital Management LLP	Mutual Fund	2026/Q3	+128,845	0.2%
Millennium Management LLC	Hedge Fund	2026/Q3	+115,403	0.2%
Schonfeld Strategic Advisors LLC	Hedge Fund	2026/Q3	+108,879	0.2%
JPMorgan Chase & Co.	Public Company	2026/Q3	+82,955	0.3%
Dimensional Fund Advisors	Mutual Fund	2026/Q3	+59,436	2.0%
Sierra Summit Advisors LLC	Family Office/Trust	2026/Q3	+59,096	0.1%
Segall Bryant & Hamill, LLC	Mutual Fund	2026/Q3	+56,052	0.1%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

Date	Insider	Title	Transaction	Shares	Price	Held after
14 Sep 2026	Rhonda Farnum	Chief Business Officer and Senior VP of Commercial & Medical Affairs	Automatic Disposition	-13,314	$17.03	213,476
19 Aug 2026	Rick Winningham	Chairperson & CEO	Sale to Issuer	-20,034	$16.95	1,726,989
19 Aug 2026	Brett Grimaud	Senior Vice President	Sale to Issuer	-7,952	$16.95	355,168
19 Aug 2026	Rhonda Farnum	Chief Business Officer and Senior VP of Commercial & Medical Affairs	Sale to Issuer	-5,667	$16.95	226,790
19 Aug 2026	Aziz Sawaf	Senior Vice President	Sale to Issuer	-8,112	$16.95	336,841
19 Aug 2026	Aine Miller	VP of Regulatory, Quality, Clinical Safety & Pharmacovigilance and Head of Ireland Office	Sale to Issuer	-6,258	$16.95	189,826
6 Jul 2026	Madison Avenue Partners, LP		Open Market Disposition	-6,964	$17.17	9,167,489
30 Jun 2026	Madison Avenue Partners, LP		Open Market Disposition	-336,697	$17.23	9,174,453
18 Jun 2026	Aine Miller	VP of Regulatory, Quality, Clinical Safety & Pharmacovigilance and Head of Ireland Office	Other Acquisition	+18,750	–	196,084
14 Jun 2026	Rhonda Farnum	Chief Business Officer and Senior VP of Commercial & Medical Affairs	Automatic Disposition	-13,314	$16.39	232,457
11 Jun 2026	Deepika Pakianathan	Independent Director	Other Acquisition	+6,009	–	64,074
11 Jun 2026	Deepika Pakianathan	Independent Director	Other Derivative Acquisition	+13,398	$16.64	13,398
11 Jun 2026	Dean Mitchell	Lead Independent Director	Other Acquisition	+6,009	–	97,213
11 Jun 2026	Dean Mitchell	Lead Independent Director	Other Derivative Acquisition	+13,398	$16.64	13,398
11 Jun 2026	Donal O'Connor	Independent Director	Other Acquisition	+6,009	–	80,213
11 Jun 2026	Donal O'Connor	Independent Director	Other Derivative Acquisition	+13,398	$16.64	13,398
11 Jun 2026	Susannah Gray	Independent Director	Other Acquisition	+6,009	–	48,146
11 Jun 2026	Susannah Gray	Independent Director	Other Derivative Acquisition	+13,398	$16.64	13,398
11 Jun 2026	Laurie Smaldone Alsup	Independent Director	Other Acquisition	+6,009	–	80,989
11 Jun 2026	Laurie Smaldone Alsup	Independent Director	Other Derivative Acquisition	+13,398	$16.64	13,398

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report date	Shares short	% of float	Days to cover
15 Sep 2026	1,686,673	3.2%	4.5
31 Aug 2026	1,618,508	3.1%	4.5
14 Aug 2026	1,714,947	3.3%	2.5
31 Jul 2026	4,168,511	8.0%	7.6
15 Jul 2026	4,306,471	8.3%	5.3
30 Jun 2026	4,502,718	8.7%	4.2

Discussion

No comments yet — be the first to weigh in on TBPH.